Kyverna Therapeutics (Kyverna Therapeutics) Accounts Payable & Accrued Expense : $16.78 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Accounts Payable & Accrued Expense?

Kyverna Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2023 ($9.27 Mil) to Dec. 2023 ($10.61 Mil) and increased from Dec. 2023 ($10.61 Mil) to Mar. 2024 ($16.78 Mil).

Kyverna Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 ($7.40 Mil) to Dec. 2022 ($7.70 Mil) and increased from Dec. 2022 ($7.70 Mil) to Dec. 2023 ($10.61 Mil).

Kyverna Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Kyverna Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Accounts Payable & Accrued Expense Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

7.40

7.70

10.61

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			7.70	-	9.27	10.61	16.78

Kyverna Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024